New Studies Confirm Safety of Semaglutide for Mental Health

Research from Sweden and the U.S. finds no significant link between semaglutide-based drugs and increased risk of depression or suicidal behavior.

Karolinska Institutet study shows no significant mental health risks for GLP-1 users in Sweden and Denmark.
University of Pennsylvania analysis of four trials supports findings, showing no correlation with depression or suicidal thoughts.
FDA continues to monitor psychiatric safety but finds no evidence of increased risk from semaglutide.
Data from over 300,000 participants collectively reassures users and healthcare providers.
Researchers emphasize the need for further studies, especially for those with pre-existing mental health conditions.